The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. Its businesses include Point-of-Care, Central Laboratory, Life Sciences, and Contract Manufacturing, serving areas such as diabetes, hematology, infectious diseases, clinical chemistry, and sports medicine.
Cyborg Score Rationale
The company trades at a market cap of £138.61M with TTM revenue of £56.04M and EBITDA of £7.92M. Revenue generation is modest relative to market cap, indicating a value-challenged position despite diversified product portfolio and global reach. Challenges include modest profitability metrics.
Top Insights
EKF develops devices, tests, and media for high-throughput, accurate analysis in central labs, ensuring reliable results and precise diagnostics.
Strong geographic presence with operations in UK, USA, Germany, and Russia, providing global distribution capacity.
Product portfolio spans point-of-care analyzers, rapid tests, reagents, and life sciences solutions across diabetes, hematology, and infectious disease segments.
Share price volatility evident with 52-week range of £0.1850-£0.3190 indicating market uncertainty.
Named Competitors
POC Diagnostic Analyzers — Global leader in point-of-care and lab diagnostics
Clinical Chemistry Systems — Largest in-vitro diagnostics company globally
Specialty Reagents & Controls — Major supplier of diagnostic equipment and reagents
Recent Developments
(February 2026) Share price trading near £0.26, relatively flat with 3.93% dividend yield
(January 2026) Market cap stable at approximately £138.61M
(August 2025) Company announcements and updates to investor communications
Open the full interactive EKF Diagnostics Holdings plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.